Gynion is a Women’s Health startup with a mission to offer millions of women worldwide safe, effective, and affordable in-office therapies helping to avoid unnecessary hysterectomies and improve and save lives. Gynion is developing a therapeutic platform for multiple indications in gynecology and dermatology.Menorrx is a therapy for Heavy Menstrual Bleeding (HMB). In the pre-clinical trial, Menorrx shows promise to be a safe and effective non-invasive in-office treatment. It is simpler, easier to use, and will cost significantly less than the alternatives. Because of the high cost and clinical limitations of the available options, millions of women receive no treatment or are compelled to undergo a hysterectomy. Menorrx presents a substantial opportunity to change that both in developed markets and low-resource countries.Clarablex is a topical gel for deep tissue ablation. It is a treatment for multiple indications in gynecology and dermatology, including cervical intraepithelial neoplasia (CIN) caused by human papillomavirus (HPV) to prevent cervical cancer. In the pre-clinical trial, Clarablex demonstrates results that are expected to be sufficient to treat CIN2+.

• theraGI's first product Arida Endoscopic Clip was acquired by a major strategic in April 2024.theraGI develops medical devices for therapeutic endoscopy. This fast-evolving clinical discipline allows endoscopic surgeons and gastroenterologists to treat complex GI tract diseases minimally invasively and avoid surgeries for millions of patients suffering from GI cancer, bleeding, anastomotic leaks, and other conditions.

Bridge Innovations is an accelerator with an established track record of taking medical device startups from concept to successful exit. We partner with inventors, founders, and CEOs to help them build their companies quickly and efficiently.

Health Haven Hub is New Haven, Connecticut’s premier healthcare innovation space and is made possible from the support of the office of Economic Development for the City of New Haven, the CT Next Innovation Places program, and the Elm City Innovation Collaborate. The Hub is an incubator for startups within the medical field that aims to become a workspace for medical innovation for the state of Connecticut and further support global innovators across the world in their early stages of development. Companies selected for hub programming receive workspace, funding, and technical and professional expertise.Health Haven Hub is comprised of three partner organizations: HealthVenture, Bridge Innovations, and Origami Innovations.

Mederi Therapeutics manufactures and markets worldwide an innovative medical system that offers proven solutions to two debilitating digestive disorders: Bowel Control Disorder (BCD) and Gastro-Esophageal Reflux Disease (GERD).Product line includes a proprietary radio frequency (RF) generator and two disposable accessories.• The generator is a sophisticated software-controlled device that regulates power delivery to four independent RF channels based on real time measurements of tissue temperature and impedance.• Disposable accessories include Secca® for treatment of BCD and Stretta® endoscopic catheter for treatment of GERD. These high complexity “smart” disposables contain a printed circuit board that actively communicates with the generator, four RF electrodes, eight temperature sensors, an irrigation and aspiration system, a centering balloon, and LED illumination.Secca® and Stretta® devices demonstrated effectiveness in numerous studies and thousands of clinical cases performed worldwide.

HET™ Bipolar System is an innovative non-surgical treatment for Internal Hemorrhoids using radio frequency (RF) energy. It is a proprietary technology that allows for the gentle, simple, and effective treatment of all symptomatic grades I and II hemorrhoids in a single procedure. The treatment targets the area above the dentate line, and its low treatment temperature minimizes collateral tissue damage.

VentralFix™ is a ventral hernia repair device for quick and easy Delivery, Deployment and Fixation (D/D/F™) of hernia mesh. The system will reduce complication and recurrence rates and accelerate an adoption of a laparoscopic approach to this procedure.

ContraMed, LLC is developing the next generation of long acting, reversible contraceptive technology for the Women's Health market.

The LumenR system is designed to improve endoscopic sub-mucosal dissection (ESD) and endoscopic mucosal resection (EMR) procedures which are less invasive alternatives to conventional surgery for the removal of precancerous lesions and malignant tumors in the gastrointestinal tract.

Pnavel Systems Inc. developed UNI-X™ Single Port Laparoscopic System that was the first single-port laparoscopic system, which included a single multi-cannula laparoscopic port and a variety of proprietary articulating curved laparoscopic instruments. The system eliminated the need for additional ports, resulting in less morbidity, improved cosmesis, and reduced cost.After successful field evaluations in Cleveland Clinic and Columbia University Medical Center, technology was acquired by Covidien in October, 2008.

Vivatone™ was the first hearing aid on the market that kept an ear canal completely opened while providing superior comfort and sound quality. Vivatone™ technology revolutionized the hearing aid market and was acquired by Starkey in 2008.

Interventional Therapies is a medical devices accelerator that developed two technologies for interventional cardiology, including a femoral artery closure device and a radiation system for prevention of re-stenosis. • AngioRad™ Intravascular Gamma Radiation System (acquired by Guidant). AngioRad™ is catheter-based radiation therapy for prevention of in-stent restenosis. After successful completion of a multicenter IDE clinical trial, technology was acquired by Guidant in 2003.• Quick-Close™ Vascular Closure System Quick-Close™ is a suture-mediated device for closure of femoral arteries. This device was successfully evaluated in a US multicenter clinical trial and received a PMA approval in early 2009.

Managed efforts of a cross-functional team to develop various surgical instrumentation, including a laser system for TMR and intravascular gamma-radiation system to prevent in-stent restenosis.